Literature DB >> 11886434

Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation.

P H Gosselaar1, A J G van-Dijk, G C de-Gast, L Polito, A Bolognesi, W C Vooijs, A F M Verheul, H G J Krouwer, J J M Marx.   

Abstract

BACKGROUND: Cytotoxic agents can be targeted successfully to cancer cells. The efficacy of such novel and potent anticancer strategies may be influenced by variables of iron metabolism.
METHODS: The in vitro cytotoxicity against glioma cells of transferrin (Tf)-based targeted toxins was compared with that of alpha-transferrin receptor (TfR)-immunotoxin.
RESULTS: Of four Tf-based targeted toxins, Tf-gelonin, Tf-pokeweed antiviral protein, Tf-momordin and Tf-saporin, inhibitory concentration 50% values against glioma-derived cell lines HS683 and U251, ranged from [4.8 +/- 1.5] x 10(-10) m for Tf-saporin to [26.9 +/- 15.3] x 10(-10) m for Tf-gelonin in [(3)H]-leucine incorporation assays. Tf-saporin and alpha-TfR-saporin-immunotoxin had similar efficacy, even in the more quantitative clonogenic assay (4-5 log kill with 1 x 10(-9) m) using the myeloma cell line RPMI 8226 and glioma cell line U251. However, on RPMI 8226, the efficacy of Tf-saporin 1 x 10(-9) m was reduced by 90% in the presence of 150 microg mL(-1)(=20% of normal plasma value) competing diferric transferrin, whereas the efficacy of the corresponding immunotoxin was affected only marginally. In addition, the efficacy of Tf-based conjugates will depend on their iron saturation state. Iron desaturation of Tf-saporin was demonstrated by [(59)Fe]-labelling, subsequent CM-Sepharose chromatography and SDS-PAGE. Desaturation led to virtually complete loss of affinity for the transferrin receptor, as determined by flow cytometry, which could be largely restored upon resaturation.
CONCLUSION: Transferrin-based toxin conjugates are strongly influenced by the presence of free transferrin and the iron saturation state. The corresponding alpha-transferrin receptor-immunotoxin does not show these disadvantages, has similar efficacy and should be preferred for further experiments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886434     DOI: 10.1046/j.1365-2362.2002.0320s1061.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Potential Screening for Cardiologist?

Authors:  Chin-Yu Lin; Yenn-Jiang Lin
Journal:  Acta Cardiol Sin       Date:  2017-05       Impact factor: 2.672

Review 2.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

3.  Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.

Authors:  Dennis J Yoon; Byron H Kwan; Felix C Chao; Theodore P Nicolaides; Joanna J Phillips; Gretchen Y Lam; Anne B Mason; William A Weiss; Daniel T Kamei
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

Review 4.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013

Review 5.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

6.  Innovative Therapies against Human Glioblastoma Multiforme.

Authors:  Annamaria Cimini; Rodolfo Ippoliti
Journal:  ISRN Oncol       Date:  2011-07-24

7.  Piperazinyl fragment improves anticancer activity of Triapine.

Authors:  Marta Rejmund; Anna Mrozek-Wilczkiewicz; Katarzyna Malarz; Monika Pyrkosz-Bulska; Kamila Gajcy; Mieczyslaw Sajewicz; Robert Musiol; Jaroslaw Polanski
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

Review 8.  Saporin-S6: a useful tool in cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Daniele Mercatelli; Maria Giulia Battelli; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2013-10-07       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.